ADC has established a solid position in the oncology pharmacopoeia. Over 1,500 clinical trials of ADCs are listed on clinicaltrials.gov, and an increasing number of drugs are entering clinical trials. It canRead More…
Like most drugs, the development interruption of ADCs is typically due to a lack of efficacy, safety issues, commercial considerations, or a combination of these factors. Since 2000, among the 97 ADCsRead More…
In 1913, the renowned German chemist Paul Ehrlich introduced the concept of the “magic bullet”, which is considered the earliest description of ADC drugs. In 2000, the FDA approved Mylotarg, the firstRead More…
Reviewing the 100-year development history of tumor therapy, it has gone through three revolutions, and also led to the revolution of chemotherapy, targeted therapy. and immunotherapy. It can be said that changeRead More…
There are more than 650 active traditional ADC drugs currently, with only 14 having been approved to enter the market, and nearly 200 products still in different clinical research stages. Among them,Read More…
Recently, combining immunotherapy with ADCs has entered clinical research, with growing evidence that ADCs may increase the efficacy of immunotherapy. Its mechanisms are varied, including inducing immunogenic cell death, dendritic cell maturation,Read More…
Compared to standard chemotherapy, ADC (antibody-drug conjugate) improves the therapeutic index, and its activity in patients with selective tumors makes it a potential partner for targeted drugs. Joint strategies can be conceivedRead More…
Although ADC drugs have greatly improved the survival benefits of patients, the duration of their objective response or clinical benefits as a monotherapy is limited due to the emergence of drug resistanceRead More…
CD33 CD33, a 67kda transmembrane glycoprotein receptor, is usually expressed in normal myeloid cells and it is the target of GO because it is preferentially overexpressed in AML cells. The intracellular immunoreceptorRead More…
Generally speaking, normal endocytosis can be divided into three stages: (1) bud formation; (2) membrane bending and vesicle maturation; and (3) membrane rupture and release into the cytoplasm. Multiple endocytosis pathways overlap,Read More…